Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cinacalcet hydrochloride
Drug ID BADD_D00469
Description Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Indications and Usage For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Marketing Status approved
ATC Code H05BX01
DrugBank ID DB01012
KEGG ID D03505
MeSH ID D000069449
PubChem ID 156418
TTD Drug ID D03YGR
NDC Product Code 65372-1165; 65977-0110; 50090-3529; 58159-055; 65862-799; 68259-1302; 55513-073; 71093-154; 63126-910; 55513-075; 53747-056; 65085-0052; 49706-2030; 65096-0114; 16436-0082; 55513-074; 70436-007; 71093-152; 53104-7699; 53296-0082; 71093-153; 50379-0016; 55111-959; 63415-0528; 70436-008; 70436-009
UNII 1K860WSG25
Synonyms Cinacalcet | Cinacalcet Hydrochloride | Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride | Sensipar | AMG 073 | KRN 1493 | AMG073
Chemical Information
Molecular Formula C22H23ClF3N
CAS Registry Number 364782-34-3
SMILES CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.002--
Immune system disorder10.02.01.001---
Infection11.01.08.002---
Multiple fractures12.04.02.009; 15.08.02.005---
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001---
Nervous system disorder17.02.10.001---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pain in extremity15.03.04.010--
Paraesthesia17.02.06.005; 23.03.03.094--
Pruritus23.03.12.001--
Rash23.03.13.001---
Seizure17.12.03.001--
Skin disorder23.03.03.007---
Tetany05.04.02.003; 14.04.01.005; 15.05.03.013---
Thrombosis24.01.01.006---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular arrhythmia02.03.04.006--
Vomiting07.01.07.003--
Musculoskeletal discomfort15.03.04.001---
Limb discomfort15.03.04.014---
Malnutrition14.03.02.004---
Metastatic neoplasm16.16.01.007---
Decreased appetite08.01.09.028; 14.03.01.005--
Chronic kidney disease20.01.03.017--
Adrenocorticotropic hormone deficiency05.03.02.005---
Multiple organ dysfunction syndrome08.01.03.057--
The 2th Page    First    Pre   2    Total 2 Pages